INN 108

Drug Profile

INN 108

Alternative Names: 5-ASA/4-APAA; mesalazine/4-aminophenylacetic acid

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innovate Biopharmaceuticals
  • Class Small molecules
  • Mechanism of Action Immunomodulators; Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity No
  • Available For Licensing Yes - Ulcerative colitis

Highest Development Phases

  • Phase I Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 06 Sep 2017 INN 108 receives Orphan Drug status for Ulcerative colitis (In children, In infants, In adolescents) in USA
  • 04 Jan 2017 INN 108 is available for licensing in (excluding USA) as of 04 Jan 2017. www.innovatebiopharma.com
  • 04 Jan 2017 Early research in Ulcerative colitis (In the elderly, In children, In infants, In adolescents) in USA (PO, Liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top